Loading...
•
Sep 28, 2024
Haemonetics Q2 2025 Earnings Report
Haemonetics reported strong results driven by portfolio evolution and market trend response.
Key Takeaways
Haemonetics Corporation reported an 8.6% increase in revenue for the second quarter of fiscal 2025, with significant growth in the Hospital business unit. The company's adjusted earnings per diluted share increased by 13.1% to $1.12. Haemonetics updated its fiscal 2025 revenue guidance and reaffirmed its adjusted operating margin, adjusted earnings per diluted share, and free cash flow guidance.
Second quarter fiscal 2025 revenue increased by 8.6% to $345.5 million compared to the prior year.
Adjusted earnings per diluted share for the second quarter of fiscal 2025 increased by 13.1% to $1.12.
The company reaffirmed its adjusted operating margin guidance, adjusted earnings per diluted share guidance and free cash flow guidance.
Cash on hand increased by $120.5 million since the end of fiscal 2024, driven by debt financing activities.
Haemonetics
Haemonetics
Haemonetics Revenue by Segment
Revenue by Segment
Plasma Revenue
CapyFin.comBlood Center Revenue
CapyFin.comHospital Revenue
CapyFin.com Forward Guidance
The Company updated its fiscal 2025 GAAP total revenue and organic revenue growth guidance and reaffirmed its adjusted operating margin guidance, adjusted earnings per diluted share guidance and free cash flow guidance.
Positive Outlook
- Total Company Reported Revenue growth: 5 - 8%
- Hospital growth: 26% - 31%
- Total Company Organic growth: 1 - 4%
- Adjusted operating margin: 23% - 24%
- Adjusted earnings per diluted share: $4.45 - $4.75
Challenges Ahead
- Plasma growth: (3 - 6)%
- Blood Center growth: (4 - 7)%
- Currency impact on total company: (0 - 1)%
- Acquisitions impact on total company: 4 - 5%
- Free cash flow: $130M - $180M
Revenue & Expenses
Visualization of income flow from segment revenue to net income